{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:52:45Z","timestamp":1790175165339,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12325-019-01115-0","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T21:16:39Z","timestamp":1571174199000},"page":"3308-3320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Choosing the Right Antifungal Agent in ICU Patients"],"prefix":"10.1007","volume":"36","author":[{"given":"Jeanne","family":"Chatelon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Cassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"J-L Vincent","year":"2009","unstructured":"Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323\u20139.","journal-title":"JAMA"},{"key":"1115_CR2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","volume":"167","author":"CMB Sague","year":"1993","unstructured":"Sague CMB, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990. J Infect Dis. 1993;167:1247\u201351.","journal-title":"J Infect Dis"},{"key":"1115_CR3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309\u201317.","journal-title":"Clin Infect Dis"},{"key":"1115_CR4","doi-asserted-by":"crossref","unstructured":"Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6. \nhttp:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-6-21\n\n. Accessed  6 Sept 2019.","DOI":"10.1186\/1471-2334-6-21"},{"key":"1115_CR5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/CCM.0b013e31819efac0","volume":"37","author":"O Leroy","year":"2009","unstructured":"Leroy O, Gangneux J-P, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005\u20132006). Crit Care Med. 2009;37:1612\u20138.","journal-title":"Crit Care Med"},{"key":"1115_CR6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","volume":"39","author":"DH Kett","year":"2011","unstructured":"Kett DH, Azoulay E, Echeverria PM, Vincent J-L, Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665\u201370.","journal-title":"Crit Care Med"},{"key":"1115_CR7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23:219.","journal-title":"Crit Care"},{"key":"1115_CR8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JCM.01398-10","volume":"49","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49:396\u20139.","journal-title":"J Clin Microbiol"},{"issue":"554","key":"1115_CR9","first-page":"e1","volume":"33","author":"A Holley","year":"2009","unstructured":"Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents. 2009;33(554):e1\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"1115_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40560-018-0342-4","volume":"6","author":"A Cortegiani","year":"2018","unstructured":"Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.","journal-title":"J Intensive Care"},{"key":"1115_CR11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/viru.26187","volume":"5","author":"J Delaloye","year":"2014","unstructured":"Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5:161\u20139.","journal-title":"Virulence"},{"key":"1115_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/00003246-199806000-00019","volume":"26","author":"JS Lundberg","year":"1998","unstructured":"Lundberg JS, Perl TM, Wiblin T, et al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med. 1998;26:1020\u20134.","journal-title":"Crit Care Med"},{"key":"1115_CR13","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","volume":"72","author":"M Bassetti","year":"2017","unstructured":"Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017;72:i39\u201347.","journal-title":"J Antimicrob Chemother"},{"key":"1115_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.2012.06805.x","volume":"1272","author":"G Dimopoulos","year":"2012","unstructured":"Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci. 2012;1272:31\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"1115_CR15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","volume":"62","author":"JCO Sardi","year":"2013","unstructured":"Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62:10\u201324.","journal-title":"J Med Microbiol"},{"key":"1115_CR16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/molecules19011085","volume":"19","author":"E Paramythiotou","year":"2014","unstructured":"Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules. 2014;19:1085\u2013119.","journal-title":"Molecules"},{"key":"1115_CR17","first-page":"286","volume":"3","author":"AC Mesa-Arango","year":"2012","unstructured":"Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Microbiol. 2012;3:286.","journal-title":"Front Microbiol"},{"key":"1115_CR18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3389\/fmicb.2018.01351","volume":"9","author":"GC de Oliveira Santos","year":"2018","unstructured":"de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, et al. Candida infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. Front Microbiol. 2018;9:1351.","journal-title":"Front Microbiol"},{"issue":"Suppl 6","key":"1115_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","volume":"20","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect. 2014;20(Suppl 6):42\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"1115_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157488407779422311","volume":"2","author":"R Bellmann","year":"2007","unstructured":"Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol. 2007;2:37\u201358.","journal-title":"Curr Clin Pharmacol"},{"key":"1115_CR21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"TJ Walsh","year":"1999","unstructured":"Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764\u201371.","journal-title":"N Engl J Med"},{"key":"1115_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"R Laniado-Labor\u00edn","year":"2009","unstructured":"Laniado-Labor\u00edn R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26:223\u20137.","journal-title":"Rev Iberoam Micol"},{"key":"1115_CR23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","volume":"36","author":"MM Roden","year":"2003","unstructured":"Roden MM, Nelson LD, Knudsen TA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003;36:1213\u201320.","journal-title":"Clin Infect Dis"},{"key":"1115_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IDR.S118892","volume":"10","author":"EL Berkow","year":"2017","unstructured":"Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237\u201345.","journal-title":"Infect Drug Resist"},{"key":"1115_CR25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/MMBR.00045-10","volume":"75","author":"RS Shapiro","year":"2011","unstructured":"Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 2011;75:213\u201367.","journal-title":"Microbiol Mol Biol Rev"},{"key":"1115_CR26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-3-319-25304-6_14","volume":"892","author":"R Prasad","year":"2016","unstructured":"Prasad R, Shah AH, Rawal MK. Antifungals: mechanism of action and drug resistance. Adv Exp Med Biol. 2016;892:327\u201349.","journal-title":"Adv Exp Med Biol"},{"key":"1115_CR27","first-page":"130","volume":"19","author":"AJ Carrillo-Mu\u00f1oz","year":"2006","unstructured":"Carrillo-Mu\u00f1oz AJ, Giusiano G, Ezkurra PA, Quind\u00f3s G. Antifungal agents: mode of action in yeast cells. Rev Espanola Quimioter. 2006;19:130\u20139.","journal-title":"Rev Espanola Quimioter"},{"key":"1115_CR28","doi-asserted-by":"crossref","first-page":"e12751","DOI":"10.1111\/tid.12751","volume":"19","author":"AH Groll","year":"2017","unstructured":"Groll AH, Townsend R, Desai A, et al. Drug\u2013drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19:e12751.","journal-title":"Transpl Infect Dis"},{"key":"1115_CR29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","volume":"45","author":"I Martin-Loeches","year":"2019","unstructured":"Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45:789\u2013805.","journal-title":"Intensive Care Med"},{"key":"1115_CR30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/AAC.02461-15","volume":"60","author":"MG Sinnollareddy","year":"2016","unstructured":"Sinnollareddy MG, Roberts MS, Lipman J, et al. In vivo microdialysis to determine subcutaneous interstitial fluid penetration and pharmacokinetics of fluconazole in intensive care unit patients with sepsis. Antimicrob Agents Chemother. 2016;60:827\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"1115_CR31","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1128\/AAC.00963-16","volume":"60","author":"JD Momper","year":"2016","unstructured":"Momper JD, Capparelli EV, Wade KC, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. Antimicrob Agents Chemother. 2016;60:5539\u201345.","journal-title":"Antimicrob Agents Chemother"},{"key":"1115_CR32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737\u201379.","journal-title":"Infection"},{"key":"1115_CR33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408\u201315.","journal-title":"N Engl J Med"},{"key":"1115_CR34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","volume":"33","author":"J Ray","year":"2011","unstructured":"Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit. 2011;33:387\u201392.","journal-title":"Ther Drug Monit"},{"key":"1115_CR35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(15)01218-0","volume":"387","author":"MA Slavin","year":"2016","unstructured":"Slavin MA, Thursky KA. Isavuconazole: a role for the newest broad-spectrum triazole. Lancet. 2016;387:726\u20138.","journal-title":"Lancet"},{"key":"1115_CR36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828\u201337.","journal-title":"Lancet Infect Dis"},{"key":"1115_CR37","unstructured":"Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. PubMed\u2014NCBI. \nhttps:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30289478\n\n. Accessed 12 Sept 2019."},{"key":"1115_CR38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","volume":"61","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Bassetti M, D\u00f6rfel D, et al. Isavuconazole shortens the QTc interval. Mycoses. 2018;61:256\u201360.","journal-title":"Mycoses"},{"key":"1115_CR39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","volume":"30","author":"JE Nett","year":"2016","unstructured":"Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am. 2016;30:51\u201383.","journal-title":"Infect Dis Clin North Am"},{"key":"1115_CR40","unstructured":"European Medicines Agency. Ecalta. EMA. 2018. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ecalta\n\n. Accessed 6 Sept 2019."},{"key":"1115_CR41","unstructured":"European Medicines Agency. Mycamine. EMA. 2018. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mycamine\n\n. Accessed 6 Sept 2019."},{"key":"1115_CR42","unstructured":"European Medicines Agency. Cancidas (previously Caspofungin MSD). EMA. 2018. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cancidas-previously-caspofungin-msd\n\n. Accessed 6 Sept 2019."},{"key":"1115_CR43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270007303764","volume":"47","author":"GC Mistry","year":"2007","unstructured":"Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol. 2007;47:951\u201361.","journal-title":"J Clin Pharmacol"},{"key":"1115_CR44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","volume":"55","author":"LC Martial","year":"2016","unstructured":"Martial LC, Br\u00fcggemann RJM, Schouten JA, et al. Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure. Clin Pharmacokinet. 2016;55:723\u201333.","journal-title":"Clin Pharmacokinet"},{"key":"1115_CR45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-011-1066-8","volume":"67","author":"I Spriet","year":"2011","unstructured":"Spriet I, Meersseman W, Annaert P, de Hoon J, Willems L. Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis. Eur J Clin Pharmacol. 2011;67:753\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"1115_CR46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkm125","volume":"60","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60:100\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1115_CR47","first-page":"e01582","volume":"61","author":"KCM van der Elst","year":"2017","unstructured":"van der Elst KCM, Veringa A, Zijlstra JG, et al. Low caspofungin exposure in patients in intensive care units. Antimicrob Agents Chemother. 2017;61:e01582.","journal-title":"Antimicrob Agents Chemother"},{"key":"1115_CR48","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2014;69:3294\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1115_CR49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","volume":"24","author":"EA Stone","year":"2002","unstructured":"Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther. 2002;24:351\u201377 (discussion 329).","journal-title":"Clin Ther"},{"key":"1115_CR50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","volume":"47","author":"JA Dowell","year":"2007","unstructured":"Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007;47:461\u201370.","journal-title":"J Clin Pharmacol"},{"key":"1115_CR51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","volume":"369","author":"E-R Kuse","year":"2007","unstructured":"Kuse E-R, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519\u201327.","journal-title":"Lancet"},{"key":"1115_CR52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883\u201393.","journal-title":"Clin Infect Dis"},{"key":"1115_CR53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-10-150","volume":"10","author":"MD Zilberberg","year":"2010","unstructured":"Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010;10:150.","journal-title":"BMC Infect Dis"},{"key":"1115_CR54","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","volume":"55","author":"D Andes","year":"2011","unstructured":"Andes D, Ambrose PG, Hammel JP, et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother. 2011;55:2113\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1115_CR55","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1097\/CCM.0b013e31818b3477","volume":"36","author":"AJ Labelle","year":"2008","unstructured":"Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967\u201372.","journal-title":"Crit Care Med"},{"key":"1115_CR56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"1115_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","volume":"19","author":"MG Sinnollareddy","year":"2015","unstructured":"Sinnollareddy MG, Roberts JA, Lipman J, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study. Crit Care. 2015;19:33.","journal-title":"Crit Care"},{"key":"1115_CR58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","volume":"44","author":"JA Dowell","year":"2004","unstructured":"Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol. 2004;44:590\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1115_CR59","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","volume":"56","author":"CJ Clancy","year":"2013","unstructured":"Clancy CJ, Nguyen MH. Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284\u201392.","journal-title":"Clin Infect Dis"},{"key":"1115_CR60","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1\u201350.","journal-title":"Clin Infect Dis"},{"key":"1115_CR61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jama.2016.16535","volume":"317","author":"A Cortegiani","year":"2017","unstructured":"Cortegiani A, Russotto V, Giarratano A. Associations of antifungal treatments with prevention of fungal infection in critically ill patients without neutropenia. JAMA. 2017;317:311\u20132.","journal-title":"JAMA"},{"key":"1115_CR62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14787210.2018.1528872","volume":"16","author":"S Keane","year":"2018","unstructured":"Keane S, Geoghegan P, Povoa P, Nseir S, Rodriguez A, Martin-Loeches I. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Rev Anti Infect Ther. 2018;16:839\u201347.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"1115_CR63","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01115-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:11:40Z","timestamp":1602630700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01115-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}